Internship
Biology Laboratory Technician Apprentice
Sartorius
5,001-10,000 employees
Laboratory instruments and bioprocess solutions
Compensation Overview
€1.2k - €1.4k/mo
Freiburg im Breisgau, Germany
In Person
Travel to Göttingen and Karlsruhe is required.
 Biology & Biotech (1) |
|---|
Get referred to Sartorius
See people who can refer or advise you
- The candidate should be interested in scientific questions.
- The candidate should have good knowledge of biology, chemistry, mathematics, and English.
- The candidate should demonstrate responsibility and independence in daily work.
- The candidate must consistently follow rules and work precisely.
- The candidate must be willing to work in product development and quality control according to exact specifications.
- The candidate should demonstrate teamwork, accuracy, care, and motivation to continue learning.
- The candidate should have good German language skills and basic English language skills.
- The candidate must be highly willing to travel to Göttingen and Karlsruhe.
- The trainee will work in various departments according to a structured training plan to learn workflows and processes.
- The trainee will assume defined tasks and responsibilities in cell culture and molecular biology methods.
- The trainee will cultivate microorganisms and cells using different methods and subsequently purify the end products.
- The trainee will document work steps and evaluate the recorded results.
- The trainee will receive support for personal and professional development.
Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Göttingen, Germany
Founded
1870
Get referred to Sartorius
See people who can refer or advise you
Simplify's Take
What believers are saying
- First-half 2026 sales reached €1.8109 billion, with profitable growth and rising free cash flow.
- January 2026 ISCC Plus certification expanded bio-circular filters and single-use products across Europe.
- June 2025 Aubagne expansion and July 2026 launches expand capacity for biologics customers.
What critics are saying
- Bio-Rad still owned roughly 38% of ordinary shares on June 30, 2026.
- July 2026 Bio-Rad restructuring signals persistent pressure to monetize its Sartorius stake.
- 2025 demand remained below pre-pandemic levels, forcing hiring freezes' reversal into selective production additions.
What makes Sartorius unique
- Bioprocess Solutions drove 80% of 2026 sales, anchored by single-use workflows.
- March 2026 CHO host line triples productivity, strengthening cell-line development economics.
- June 2026 LFB collaboration links CLD, analytics, and GMP manufacturing into one pathway.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Flexible Work Hours
Wellness Program
Professional Development Budget
Company News
Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.
Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.
Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.
May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.
Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.